DOI: 10.19102/icrm.2021.120701

THE JOURNAL OF INNOVATIONS IN CARDIAC RHYTHM MANAGEMENT<sup>IM</sup>

**DEVICE THERAPY** 

### LAA CLOSURE

## CASE REPORT

# Percutaneous Extraction of a Migrated WATCHMAN™ Device After Seven Months

ABHISHEK MAAN, MD, ScM, MOHIT K. TURAGAM, MD, MS, SRINIVAS R. DUKKIPATI, MD, and VIVEK Y. REDDY, MD<sup>1</sup>

<sup>1</sup>Helmsley Electrophysiology Center, Division of Cardiac Electrophysiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

**ABSTRACT.** Rarely, a left atrial appendage closure device may chronically migrate to an unfavorable position postoperatively, requiring removal. We present the details of a case in which a WATCHMAN<sup>TM</sup> device (Boston Scientific, Natick, MA, USA) implanted seven months prior was found to have migrated with protrusion 0.91 cm outside the left atrial appendage together with a 90° tilt and peridevice leakage. Adopting a femoral arterial retrograde approach, a 27-mm WATCHMAN<sup>TM</sup> device was temporarily positioned in the ascending aorta for cerebroembolic protection, never released from the connecting wire. Extraction of the original WATCHMAN<sup>TM</sup> device was performed using an endoscopic grasping tool, with subsequent device re-implantation of a new device and removal of the temporarily positioned device in the ascending aorta.

**KEYWORDS.** Atrial fibrillation, endoscopic grasping tool, device extraction, Watchman.

ISSN 2156-3977 (print) ISSN 2156-3993 (online) CC BY 4.0 license

© 2021 Innovations in Cardiac Rhythm Management

### Case presentation

An 84-year-old man with persistent atrial fibrillation (CHA<sub>2</sub>DS<sub>2</sub>-VASc score of six points) was referred because of the migration of a 24-mm WATCHMAN™ device (Boston Scientific, Natick, MA, USA) implanted seven months prior. His additional medical history was notable for chronic kidney disease and having undergone dual-chamber pacemaker implantation in 2017 for sinus node dysfunction. At the time of the current case, the patient was on a renally adjusted dose of rivaroxaban for thromboprophylaxis. Transesophageal echocardiography (TEE) revealed a loss of device compression with consequent protrusion 0.91 cm outside the left atrial appendage

Dr. Maan reports the reception of research grants from Medtronic, Biotronik, and Biosense Webster; research equipment support from QT Medical and Bardy Rx; and equity in Proteostasis Inc. and NovaVax. Dr. Reddy reports the receipt of grant support from and

Manuscript received December 14, 2020. Final version accepted January 29, 2021.


report no conflicts of interest for the published content.

an unpaid consultant role with Boston Scientific. The other authors

Address correspondence to: Vivek Y. Reddy, MD, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P. O. Box 1030, New York, NY 10029, USA. E-mail: vivek.reddy@mountsinai.org.

together with a 90° tilt and peridevice leakage (Figure 1 and Videos 1A–1C).

Under general anesthesia, an extraction procedure was performed with TEE, intracardiac echocardiographic, and fluoroscopy guidance. Adopting a femoral arterial retrograde approach, a 27-mm WATCHMAN<sup>TM</sup> device was temporarily positioned in the ascending aorta for cerebroembolic protection, never released from the connecting wire (ie, "Watchman in Ascending Aorta for Systemic Protection" technique) (Videos 2A and 2B). A weight-based heparin intravenous bolus dose was given to achieve an activated clotting time of greater than 250 seconds prior to pursuing transseptal access. A 23-French nondeflectable sheath (Micra<sup>TM</sup>; Medtronic, Minneapolis, MN, USA) was advanced into the right atrium, through which a 12-French deflectable sheath (FlexCath Advance™; Medtronic) was placed transseptally. A 2.4 mm × 20 cm Raptor™ grasping device (US Endoscopy, Mentor, OH, USA) (Figure 1) was advanced through the 12-French sheath to grasp the WATCHMAN<sup>TM</sup> device. With sustained traction, the device was dislodged from the left atrial appendage into the 23-French sheath (Figure 1 and Video 3). This older WATCHMAN<sup>TM</sup> device was negative for any surface thrombi or debris. Subsequently, placement of a new



**Figure 1: A:** The endoscopic grasping tool with a hybrid jaw configuration combining both alligator and rat tooth capabilities for enhanced gripping. **B:** To remove the migrated WATCHMAN™ device, a second device was temporarily positioned in the ascending aorta for embolic protection **C:** and the grasping tool was used to retrieve the device. **D:** Grasping tool just prior to retrieving the WATCHMAN™ device.

Table 1: Description of the Step-by-step Approach Adopted for WATCHMAN™ Extraction

Procedural Step	Purpose
TEE	Performed as the initial step to exclude thrombus in the LAA and LAA prior to pursuing further procedural steps
Vascular access	Placement of 8.5-Fr sheath in the left femoral vein, 11-Fr sheath in the left femoral vein, and 5-Fr arterial sheath with subsequent upgrade to 8-Fr in the left common femoral artery
Further exchange	The 8.5-Fr sheath was exchanged for an SL-1 sheath
Transseptal access	Using a Brockenbrough needle, the SL-1 sheath was exchanged for a 23-Fr Micra™ leadless pacemaker sheath; then, another FlexCath sheath was advanced via the leadless sheath into the LA
Arterial exchange	The 8-Fr arterial sheath was exchanged for the 14-Fr WATCHMAN™ sheath, which was placed in the ascending aorta
Embolic protection	A 27-mm WATCHMAN™ device was placed in the ascending aorta
WATCHMAN™ extraction	The Raptor™ device was then advanced via the 12-Fr Flex sheath to placement in a coaxial manner to grasp the older WATCHMAN™ device from the LAA
Sheath exchange	A new 14-Fr WATCHMAN™ sheath was then placed into the LA
TEE and LAA angiography	LAA measurements were collected and an angiogram of the LAA was created using a pigtail catheter
New WATCHMAN™ device implantation	A new 24-mm WATCHMAN™ device was delivered and positioned in the LAA; its positioning was further verified using TEE and fluoroscopy
Vascular access closure	The venous access site was closed using a figure-of-eight suture, while the arterial access route was closed using a Perclose ProGlide™ tool (Abbott, Chicago, IL, USA)

LA: left atrium; LAA: left atrial appendage; TEE: transesophageal echocardiography.

24-mm WATCHMAN<sup>TM</sup> device was performed with good apposition; the temporary WATCHMAN<sup>TM</sup> device in the aorta was removed at this point. The procedural steps are summarized in **Table 1.** Follow-up TEE performed at four months confirmed stable device positioning without significant peridevice leakage.

In unusual instances, a left atrial appendage closure device may be found to have chronically migrated to an unfavorable position, requiring removal. This case demonstrates the safety and feasibility of WATCH-MAN<sup>TM</sup> extraction using an endoscopic grasping tool and subsequent device re-implantation.<sup>2,3</sup> We preferred the use of the Raptor tool given the chronicity of the previously placed WATCHMAN<sup>TM</sup> device, which may not have been suitable for retrieval using a snare or biopsy bioptome. The decision to place a WATCHMAN<sup>TM</sup> device

temporarily in the ascending aorta was driven by the limitations of currently available embolic protection devices to prevent peripheral embolization.

#### References

- 1. Yadav PK, Wang DD, Eng MH, O'Neill WW. Watchman in ascending aorta for systemic protection (WAASP): Novel use of Watchman in ascending aorta for embolic protection—first in man. *Catheter Cardiovasc Interv.* 2018;92(2):433–436.
- 2. Turagam MK, Neuzil P, Dukkipati SR, et al. Percutaneous retrieval of left atrial appendage closure devices with an endoscopic grasping tool. *JACC Clin Electrophysiol*. 2020;6(4):404–413.
- 3. Afzal MR, Ellis CR, Gabriels J, et al. Percutaneous approaches for retrieval of an embolized or malpositioned left atrial appendage closure device: a multicenter experience. *Heart Rhythm.* 2020;17(9):1545–1553.